The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA has controversially granted accelerated approval to aducanumab and has opined that the reduction of amyloid is reasonably likely to predict clinical benefit 7,9,[98][99][100][101][102][103][104][105][106][107] .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 2×
“ing anti-Aß monoclonal antibodies including lecanemab [9], gantenerumab [10], and donanemab [11] and the many”
BackgroundSelf-citationSwanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847
Self-citationStructural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 369
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J. L., Feldman, H., & Scheltens, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 252
Self-citationAlexander, G. C., Emerson, S., & Kesselheim, A. S. (2021) · JAMA · doi:10.1001/jama.2021.3854 · Cited by 240
Klein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212
IMMEDIATE CARE OF ACUTE BLUNT LARYNGEAL TRAUMA
Nahum, A. M. (1969) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-196902000-00003 · Cited by 57
Sabbagh, M. N., & Cummings, J. L. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12235 · Cited by 47
Self-citation
Research works printed but not linked: 2
- Haeberlein SB, von Hehn C, Tian Y, et al., editors. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease. San Diego, CA: 12th Clinical Trials on Alzheimer's Disease; 2019.
- Food and Drug Administration, Center for Drug Evaluation and Research. Formal meetings between the FDA and sponsors or applicants of PDUFA Products Guidance for Industry. Silver Spring, MD: Office of Communictions, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration; 2017.
Cited by
Sorted by citations
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Cummings, J. L., Osse, A. M. L., Cammann, D., Powell, J., & Chen, J. (2023) · BioDrugs · doi:10.1007/s40259-023-00633-2 · Cited by 420
Self-citationJeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01569-z · Cited by 293
Cummings, J. L. (2023) · Drugs · doi:10.1007/s40265-023-01858-9 · Cited by 266
Self-citationQuantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
Withington, C., & Turner, R. S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.862369 · Cited by 158
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Ross, E. L., Weinberg, M. S., & Arnold, S. E. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0315 · Cited by 151
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Walgrave, H., Zhou, L., Strooper, B. D., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 137
Rinauro, D. J., Chiti, F., Vendruscolo, M., & Limbocker, R. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00651-2 · Cited by 138
Neuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 131
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9343514 · Cited by 129
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Can we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?
Kurkinen, M. T., Fułek, M., Fułek, K., Beszłej, J. A., Kurpas, D., & Leszek, J. (2023) · Biomolecules · doi:10.3390/biom13030453 · Cited by 105
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99
Neuropathology of Anti-Amyloid-β Immunotherapy: A Case Report
Castellani, R. J., Shanes, E. D., McCord, M., Reish, N. J., Flanagan, M. E., Mesulam, M. M., & Jamshidi, P. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221305 · Cited by 85
Complement System in Alzheimer’s Disease
Shah, A., Kishore, U., & Shastri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413647 · Cited by 76
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 77
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71
Self-citationBorrajo, M. L., & Alonso, M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01086-2 · Cited by 76
Patharapankal, E. J., Ajiboye, A. L., Mattern, C., & Trivedi, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010066 · Cited by 75
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Nunes, D., Loureiro, J. A., & Pereira, M. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112296 · Cited by 68
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
Cheng, F., Wang, F., Tang, J., Zhou, Y., Fu, Z., Zhang, P., Haines, J. L., Leverenz, J. B., Gan, L., Hu, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101379 · Cited by 63
Self-citationIndole-Based Compounds in the Development of Anti-Neurodegenerative Agents
Barresi, E., Baglini, E., Poggetti, V., Castagnoli, J., Giorgini, D., Salerno, S., Taliani, S., & Settimo, F. D. (2024) · Molecules · doi:10.3390/molecules29092127 · Cited by 62
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 54
Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53
“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112746 · Cited by 50
Kršek, A., & Batičić, L. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4020020 · Cited by 50
Digital Technologies to Prevent Social Isolation and Loneliness in Dementia: A Systematic Review
Kaur, H., Kernaghan, D., Schoonmade, L. J., Egan, K. J., & Pot, A. M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220438 · Cited by 47
Small-molecule theranostics in Alzheimer's disease
Sarabia‐Vallejo, Á., López‐Alvarado, P., & Menéndez, J. C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115382 · Cited by 48
Prados, M., Liu, Y., Jun, H., Lam, J., & Mattke, S. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12578 · Cited by 42
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 40
Wasielewska, J. M., Chaves, J. C. S., Johnston, R. L., Milton, L. A., Hernández, D., Chen, L., Song, J. H., Lee, W., Leinenga, G., Nisbet, R. M., et al. (2022) · Theranostics · doi:10.7150/thno.72685 · Cited by 41
Adenosine receptor signalling in Alzheimer’s disease
Trinh, P. N. H., Baltos, J., Hellyer, S. D., May, L. T., & Gregory, K. J. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09883-1 · Cited by 43
Bajaj, S., Jain, S., Vyas, P., Bawa, S., & Vohora, D. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.06.022 · Cited by 41
Sanchez-Varo, R. M., Sánchez‐Mejías, E., Fernandez-Valenzuela, J. J., Castro, V. D., Mejias‐Ortega, M., Gómez-Arboledas, Á., Jiménez, S., Sanchez-Mico, M. V., Trujillo‐Estrada, L., Moreno‐González, I., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.752594 · Cited by 42
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 40
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
Moreira, D. A., Santos, S. D., Leiro, V., & Pêgo, A. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041054 · Cited by 39
“Real world” eligibility for aducanumab
Canevelli, M., Rossi, P. D., Astrone, P., Consorti, E., Vanacore, N., & Cesari, M. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17390 · Cited by 36
Implications of Microorganisms in Alzheimer’s Disease
Yadav, P., Lee, Y., Panday, H., Kant, S., Bajwa, N., Parashar, R., Jha, S. K., Jha, N. K., Nand, P., Lee, S., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100314 · Cited by 37
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 37
The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer’s disease
Musardo, S., Therin, S., Pelucchi, S., D’Andrea, L., Stringhi, R., Ribeiro, A., Manca, A., Balducci, C., Pagano, J., Sala, C., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.024 · Cited by 36
Targeting epigenetics: A novel promise for Alzheimer’s disease treatment
Jeremic, D., Jiménez‐Díaz, L., & Navarro‐López, J. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102003 · Cited by 36
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 43
Blood-based biomarkers in Alzheimer’s disease: a mini-review
Padala, S. P., & NEWHOUSE, P. A. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01114-1 · Cited by 39
A History of Senile Plaques: From Alzheimer to Amyloid Imaging
Beach, T. G. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac030 · Cited by 37
Brain simulation augments machine‐learning–based classification of dementia
Triebkorn, P., Stefanovski, L., Dhindsa, K., Díaz-Cortés, M.-A., Bey, P., Bülau, K., Pai, R. K., Spiegler, A., Solodkin, A., Jirsa, V., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12303 · Cited by 31
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Poliwoda, S., Kaye, R. J., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.37023 · Cited by 35
Sighencea, M. G., Popescu, R. Ș., & Trifu, S. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212311 · Cited by 33
Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
Knopman, D. S., & Perlmutter, J. S. (2021) · Neurology · doi:10.1212/wnl.0000000000012452 · Cited by 32
On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease
Kriška, J., Heřmanová, Z., Knotek, T., Turečková, J., & Anděrová, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189689 · Cited by 33
“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
Padovani, A., Caratozzolo, S., Rozzini, L., Pilotto, A., Benussi, A., & Tedeschi, G. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17530 · Cited by 31
The role of basket trials in drug development for neurodegenerative disorders
Cummings, J. L., Montes, A., Kamboj, S., & Cacho, J. R. F. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01015-6 · Cited by 31
Self-citationDave, B. P., Shah, Y. B., Maheshwari, K. G., Mansuri, M. K. A., Prajapati, B., Postwala, H. I., & Chorawala, M. R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01408-7 · Cited by 33
Jin, M., & Noble, J. M. (2024) · eNeuro · doi:10.1523/eneuro.0088-24.2024 · Cited by 31
Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside
Musiek, E. S., Gómez‐Isla, T., & Holtzman, D. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci154889 · Cited by 30
Nirogi, R., Ieni, J., Goyal, V. K., Ravula, J., Jetta, S., Shinde, A., Jayarajan, P., Benade, V., Palacharla, V. R. C., Dogiparti, D. K., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12307 · Cited by 29
Self-citationRecent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia
Ni, R., & Nitsch, R. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.751897 · Cited by 30
The amyloid state of proteins: A boon or bane?
Hassan, M. N., Nabi, F., Khan, A. N., Hussain, M. S., Siddiqui, W. A., Uversky, V. N., & Khan, R. H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.115 · Cited by 30
Wang, Y., Wang, K., Yan, J., Zhou, Q., & Wang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213886 · Cited by 32
An insider's perspective on FDA approval of aducanumab
Wang, Y. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12382 · Cited by 28
Dementia Prevention and Individual and Socioeconomic Barriers: Avoiding “Lifestyle” Stigma
Wilson, N., & Anstey, K. J. (2023) · The Gerontologist · doi:10.1093/geront/gnad130 · Cited by 29
Zhang, P., Hou, Y., Tu, W., Campbell, N. L., Pieper, A. A., Leverenz, J. B., Gao, S., Cummings, J. L., & Cheng, F. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12819 · Cited by 31
Self-citationYeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28
Proteostasis unbalance in prion diseases: Mechanisms of neurodegeneration and therapeutic targets
Thellung, S., Corsaro, A., Dellacasagrande, I., Nizzari, M., Zambito, M., & Florio, T. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.966019 · Cited by 26
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations
Rodriguez‐Porcel, F. E., Wyman‐Chick, K. A., Abdelnour, C., Toledo, J. B., Ferreira, D., Urwyler, P., Weil, R. S., Kane, J. P. M., Pilotto, A., Rongve, A., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00299-w · Cited by 28
Devi, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1213968 · Cited by 29
Neurodegenerative Diseases: New Hopes and Perspectives
Bhat, M. A., & Dhaneshwar, S. S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230907093451 · Cited by 29
Selenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer’s Disease
Barbosa, F. A. R., Canto, R. F. S., Teixeira, K. F., de Souza, A. S., de Oliveira, A. S., & Braga, A. L. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220224161454 · Cited by 26
New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders
Liu, J., Duan, W., Deng, Y., Zhang, Q., Li, R., Long, J., Waqas, A., Gu, C., Qiu, Y., Cai, H., et al. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2203058 · Cited by 28
Syed, A. U., Liang, C., Patel, K. K., Mondal, R., Kamalia, V. M., Moran, T. R., Ahmed, S. T., & Mukherjee, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310808 · Cited by 26
Aducanumab in Alzheimer’s Disease: A Critical Update
Ashique, S., Sirohi, E., Kumar, S., Rihan, M., Mishra, N., Bhatt, S., Gautam, R. K., Singh, S. K., Gupta, G., Chellappan, D. K., et al. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230727103553 · Cited by 27
Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update
Khan, S. S., Khatik, G. L., & Datusalia, A. K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411083922 · Cited by 25
Sandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 29
Padala, S. P., & Yarns, B. C. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220023 · Cited by 24
Petrisko, T. J., Gómez-Arboledas, Á., & Tenner, A. J. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.09.003 · Cited by 23
Sun, F., Zhao, J. J., Zhang, H., Shi, Q., Liu, Y., Robert, A., Liu, Q., & Meunier, B. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00455 · Cited by 24
Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains
Mukherjee, S., Dubois, C., Perez, K. A., Varghese, S., Birchall, I. E., Leckey, M., Davydova, N., McLean, C., Nisbet, R. M., Roberts, B. R., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15713 · Cited by 22
Séguy, L., Groo, A., & Malzert‐Fréon, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.022 · Cited by 23
Marín, A., DeCaro, R. E., Schiloski, K. A., El‐Shaar, A., Dwyer, B. C., Vives‐Rodriguez, A., Palumbo, R., Turk, K. W., & Budson, A. E. (2022) · JMIR Formative Research · doi:10.2196/34450 · Cited by 22
MicroRNAs in Learning and Memory and Their Impact on Alzheimer’s Disease
Wang, I., Ho, P., & Tsai, K. (2022) · Biomedicines · doi:10.3390/biomedicines10081856 · Cited by 24
An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
Boopathi, S., Poma, A. B., & Garduño‐Juárez, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910798 · Cited by 20
Wang, G., Liu, L., Li, Y., Aschenbrenner, A. J., Bateman, R. J., Delmar, P., Schneider, L. S. S., Kennedy, R., Cutter, G., & Xiong, C. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12286 · Cited by 20
Punyakoti, P., Behl, T., Sehgal, A., Yadav, S., Sachdeva, M., Anwer, M. K., Vargas-De-La-Cruz, C. B., Venkatachalam, T., Naqvi, M., Verma, R., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110539 · Cited by 20
Huang, L., Zeng, Y., Li, Y., Zhu, Y., He, Y., Liu, Y., Robert, A., & Meunier, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122691 · Cited by 18
Webberley, T. S., Bevan, R. J., Kerry-Smith, J., Dally, J., Michael, D. R., Thomas, S., Rees, M. E., Morgan, J. E., Marchesi, J. R., Good, M. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054683 · Cited by 24
Mo, H., Kim, J., Kim, J. Y., Kim, J. W., Han, H., Choi, S. H., Rim, Y. A., & Ju, J. H. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00384-8 · Cited by 21
Hoffmann, T., Rahfeld, J., Schenk, M., Ponath, F., Makioka, K., Hutter‐Paier, B., Lues, I., Lemere, C. A., & Schilling, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111791 · Cited by 23
Self-citationNow is the Time to Improve Cognitive Screening and Assessment for Clinical and Research Advancement
Ashford, J. W., Schmitt, F. A., Bergeron, M. F., Bayley, P. J., Clifford, J. O., Xu, Q., Liu, X., Zhou, X., Kumar, V., Herman Buschke, L., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220211 · Cited by 18
Utomo, R. Y., Sugie, A., Okada, S., Miura, K., & Nakamura, H. (2022) · Chemical Communications · doi:10.1039/d1cc07000b · Cited by 18
Marsool, M. D. M., Prajjwal, P., Reddy, Y. B., Marsool, A. D. M., Lam, J. R., & Nandwana, V. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101547 · Cited by 18
Francisco, T. N., Malafaia, D., Melo, L., Silva, A. M. S., & Albuquerque, H. M. T. (2024) · ACS Omega · doi:10.1021/acsomega.3c10417 · Cited by 18
Donanemab: Not two without a third
Kurkinen, M. T. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/172673 · Cited by 18
The Effects and Mechanisms of Xanthones in Alzheimer’s Disease: A Systematic Review
Pang, L. W., Hamzah, S. B., Tan, S. L. J., Mah, S. H., & Yow, H.-Y. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04005-8 · Cited by 19
Marcolini, S., Frentz, I., Sánchez-Catasús, C. A., Mondragón, J. D., Feltes, P. K., van der Hoorn, A., Borra, R., Ikram, M. A., Dierckx, R., & Deyn, P. P. D. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101661 · Cited by 16
Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach
Meghana, G. S., Gowda, D., Chidambaram, S. B., & Osmani, R. A. M. (2023) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2023.103510 · Cited by 17
Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease
Boada, M., Martínez‐Lage, P., Serrano-Castro, P. J., Costa, M., & Páez, A. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1960823 · Cited by 15
Metadata
- Authors
- Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S.
- Affiliations
- University of Nevada, Las Vegas (US)
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- Cleveland Clinic (US)
- Brown University (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Alzheimer's Research & Therapy
- Published
- 2021-05-10
- Volume
- 13
- Issue
- 1
- Pages
- 98-98
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC8111757
- OpenAlex
- W3161140821
- Cited by
- 224
- References
- 19
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 31 · 2023: 52 · 2022: 87 · 2021: 31
- FWCI
- 31.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- National Institute on Aging (R01AG053798, P20AG068053, R35AG71476)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- aducanumab, amyloid-beta, Alzheimer's disease, anti-amyloid therapy, clinical benefit
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Amyloid beta-Peptides, Amyloidogenic Proteins, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
